Silence Therapeutics (SLN) Expected to Announce Earnings on Thursday

Silence Therapeutics (NASDAQ:SLN) will likely be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Silence Therapeutics to post earnings of ($0.33) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 8:00 AM ET.

Silence Therapeutics Trading Up 0.8%

NASDAQ:SLN opened at $5.04 on Tuesday. Silence Therapeutics has a 12 month low of $1.97 and a 12 month high of $7.78. The stock has a market capitalization of $238.04 million, a price-to-earnings ratio of -3.73 and a beta of 1.35. The firm has a fifty day simple moving average of $5.44 and a two-hundred day simple moving average of $5.75.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Boothbay Fund Management LLC grew its holdings in Silence Therapeutics by 1.0% during the second quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock worth $1,464,000 after buying an additional 2,409 shares in the last quarter. Massar Capital Management LP purchased a new position in Silence Therapeutics during the 2nd quarter worth $115,000. UBS Group AG grew its stake in shares of Silence Therapeutics by 34.5% in the 3rd quarter. UBS Group AG now owns 307,363 shares of the company’s stock worth $1,595,000 after acquiring an additional 78,854 shares in the last quarter. Two Sigma Investments LP raised its holdings in shares of Silence Therapeutics by 6.6% in the third quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock valued at $328,000 after purchasing an additional 3,935 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of Silence Therapeutics in the third quarter valued at about $112,000. Institutional investors own 98.73% of the company’s stock.

Analyst Upgrades and Downgrades

SLN has been the subject of a number of research analyst reports. Wall Street Zen raised Silence Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $32.60.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.